Free Trial

Cabot (NYSE:CBT) Issues Quarterly Earnings Results

Cabot logo with Basic Materials background

Cabot (NYSE:CBT - Get Free Report) released its earnings results on Monday. The specialty chemicals company reported $1.90 earnings per share for the quarter, beating analysts' consensus estimates of $1.86 by $0.04, Zacks reports. The business had revenue of $936.00 million during the quarter, compared to the consensus estimate of $1.02 billion. Cabot had a net margin of 10.60% and a return on equity of 26.79%. The firm's revenue for the quarter was down 8.1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.78 earnings per share. Cabot updated its FY 2025 guidance to 7.150-7.500 EPS.

Cabot Stock Performance

CBT traded up $1.41 during trading on Thursday, hitting $74.41. The stock had a trading volume of 289,195 shares, compared to its average volume of 400,169. The company's 50-day moving average price is $80.45 and its 200 day moving average price is $91.79. The firm has a market capitalization of $4.03 billion, a P/E ratio of 9.88, a PEG ratio of 0.74 and a beta of 0.91. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.29 and a current ratio of 2.00. Cabot has a twelve month low of $71.64 and a twelve month high of $117.46.

Cabot Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 30th will be issued a $0.45 dividend. This represents a $1.80 annualized dividend and a yield of 2.42%. The ex-dividend date is Friday, May 30th. This is a positive change from Cabot's previous quarterly dividend of $0.43. Cabot's dividend payout ratio is 22.84%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on CBT shares. UBS Group cut their target price on Cabot from $93.00 to $83.00 and set a "neutral" rating on the stock in a research report on Monday, April 7th. StockNews.com cut shares of Cabot from a "buy" rating to a "hold" rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. reduced their price target on shares of Cabot from $105.00 to $85.00 and set an "underweight" rating for the company in a research report on Friday, February 21st.

Read Our Latest Research Report on CBT

About Cabot

(Get Free Report)

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.

Read More

Earnings History for Cabot (NYSE:CBT)

Should You Invest $1,000 in Cabot Right Now?

Before you consider Cabot, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cabot wasn't on the list.

While Cabot currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks You’ve Never Heard Of That I’m Buying Nonstop in 2025
3 Sectors With Massive Momentum You Can’t Afford to Miss
Palantir’s Big Moves: Profit-Taking, Price Targets & AI Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines